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Abstract
 
CD40, a member of the tumor necrosis factor receptor family, and the Epstein-Barr virus–
encoded oncoprotein latent membrane protein 1 (LMP1) share several tumor necrosis factor
receptor–associated factor (TRAF) adaptor proteins for signaling. Among these, TRAF3 was
the first identified to directly bind both receptors, yet its role remains a mystery. To address
this, we generated B cell lines deficient in TRAF3 by homologous recombination. We found
that CD40 signals were normal in the absence of TRAF3, with the exception of moderately
enhanced c-Jun NH
 
2
 
-terminal kinase (JNK) activation and antibody secretion. In sharp contrast,
LMP1 signaling was markedly defective in TRAF3
 
 
 
/
 
 
 
 B cells. LMP1-induced activation of
JNK and nuclear factor 
 
 
 
B, up-regulation of CD23 and CD80, and antibody secretion were
substantially affected by TRAF3 deficiency. Reconstitution of TRAF3 expression decreased
CD40-induced JNK activation and antibody secretion, and fully restored LMP1 signaling.
Although TRAF2 is widely believed to be important for LMP1 function, LMP1 signaling was
intact in TRAF2
 
 
 
/
 
 
 
 B cells. Our data reveal that CD40 and LMP1 unexpectedly use TRAF3
in different ways, and that TRAF3 is required for LMP1-mediated activation of B cells.
Key words: TNF-R family • Epstein-Barr virus • antibody secretion • signal transduction • B cell
 
Introduction
 
TNF-R–associated factor (TRAF) 3 was first identified as a
protein associated with CD40 (1, 2). Surprisingly, another
work identified the same protein as a factor that binds to latent
membrane protein 1 (LMP1), the oncoprotein encoded by
the human pathogen EBV (3). This finding provided the
first connection between the signal transduction pathways
of CD40 and LMP1, two membrane proteins without appar-
ent structural homology.
CD40, a member of the TNF-R superfamily, is a trans-
membrane receptor on B lymphocytes and other cell types,
including dendritic cells, monocytes/macrophages, mast
cells, fibroblasts, and endothelial cells, as well as certain
activated T lymphocytes (4–7). Its ligand, CD154, is expressed
primarily on activated CD4
 
 
 
 T cells (5, 6). The CD40/
CD154 interaction is crucial for T cell–dependent humoral
immunity, regulating B cell proliferation, Ig isotype
switching, formation of germinal centers, and development
of memory B cells (4–6). CD40 depends on the TRAF
family of cytoplasmic adaptor proteins for signaling (6, 8).
TRAF2, -3, and -6 could directly bind to CD40, whereas
TRAF1 and -5 may associate with CD40 through interactions
with TRAF2 and -3, respectively (4–6). Upon ligand binding,
the trimerization of CD40 is triggered by CD154 and allows
the association of TRAFs, which function as adaptor proteins
to transduce signals to downstream molecules (4–6).
LMP1 is the only EBV-encoded protein that alone can
transform rodent fibroblasts in vitro (9, 10). Transgenic
mice expressing LMP1 under the control of the mouse IgH
enhancer and a V
 
H
 
 promoter develop B cell lymphomas at
an accelerated rate as they age (11). These findings together
with a variety of other analyses indicate that LMP1 is a major
contributing factor to the development of EBV-associated
lymphoproliferative disease and lymphomas (12, 13). LMP1
is an integral membrane protein with a short cytoplasmic
NH
 
2
 
-terminal domain, six transmembrane domains, and
a long cytoplasmic COOH-terminal tail. The six trans-
membrane domains of LMP1 spontaneously aggregate and
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oligomerize within the plasma membrane, and are respon-
sible for the ligand-independent constitutive activation of
the protein. However, the cytoplasmic carboxyl terminus
(CCT) appears to be the major region required for signal-
ing itself (13–15). Adaptor proteins able to interact with the
CCT of LMP1 were found to be members of the TRAF
family, including TRAF1, -2, -3, and -5 (3, 16–18). Subse-
quently, it was documented that LMP1 closely mimics
most of the signaling events and effector functions of CD40
in B lymphocytes, including activation of kinases and tran-
scription factors, up-regulation of adhesion molecules and
costimulatory molecules, and secretion of antibodies and
cytokines. However, unlike CD40, LMP1 signals to B cells
in a dysregulated manner, leading to amplified and sus-
tained B cell activation (13, 19–21).
To understand how CD40 and LMP1 activate B cells, it
is important to elucidate how each TRAF molecule par-
ticipates in signaling. Despite its likely importance, little is
yet known about the role of TRAF3. CD40 or LMP1
mutants specifically defective only in TRAF3 binding
have not been created because the binding sites for
TRAF1, -2, -3, and -5 on CD40 or LMP1 overlap (5, 8,
13, 22). Papers in which overexpressed dominant-negative
(DN) or WT TRAF3 was used suggest that TRAF3 plays
a negative role in both CD40- and LMP1-mediated sig-
naling (8, 12, 13). However, again, the overlap in TRAF
binding sites prevents clear interpretation of these results.
Alternatively, TRAF3-deficient mice have been generated
in an attempt to better understand its role in signaling.
Unfortunately, these mice die within 10 d of birth (23),
limiting their use in delineating the specific role of
TRAF3 in signaling by CD40, and particularly, by LMP1.
Thus, we have used a novel somatic cell gene targeting ap-
proach to generate TRAF3
 
 
 
/
 
 
 
 mouse B cell lines and
have compared CD40 and LMP1 signaling in WT and
TRAF3
 
 
 
/
 
 
 
 B cells. We elected to focus on B cells because
they are the major cell type that express CD40 and are also
the principle targets of EBV infection in vivo. Surpris-
ingly, we found that CD40 and LMP1 use TRAF3 in dif-
ferent ways. CD40 signals are either independent of, or
negatively regulated by TRAF3, whereas LMP1 requires
TRAF3 for c-Jun NH
 
2
 
-terminal kinase (JNK) and nuclear
factor 
 
 
 
B (NF-
 
 
 
B) activation, antibody secretion, and
CD80 up-regulation. We have also generated B cell lines
deficient in TRAF2 (24) or TRAF1 (unpublished data),
and find, in contrast to previous papers (12, 13), that these
TRAFs are not critical for many LMP1-mediated B cell
activation events.
 
Materials and Methods
 
Cell Lines. 
 
The mouse B cell lines CH12.LX and A20.2J
have been described previously (25, 26). Generation and charac-
terization of TRAF2
 
 
 
/
 
 
 
 CH12.LX and A20.2J cells has been de-
scribed in detail elsewhere (24), and production of TRAF1
 
 
 
/
 
 
 
CH12.LX will be reported elsewhere (unpublished data). Cells
were cultured in RPMI 1640 supplemented with 10% FCS, 10
 
 
 
M 
 
 
 
-mercaptoethanol, and antibiotics (BCM-10) as described
previously (20). 
 
Spodoptera frugiperda
 
 (Sf9) cells infected with WT
baculovirus or recombinant baculovirus expressing mouse or hu-
man CD154 were prepared as described previously (27, 28).
 
Generation of TRAF3
 
 
 
/
 
 
 
 Mouse B Cell Lines. 
 
The mTRAF3
gene targeting construct was transfected by electroporation into
subclones of the mouse B cell lines CH12.LX and A20.2J, already
stably expressing LacR as described previously (29). Transfected
cells were selected with geneticin and further screened by geno-
mic PCR as described previously (24) using primer set 1 (neo-C
and mT3-BT6) and set 2 (neotailA and mT3-S4) (Fig. 1 B). Cor-
rectly targeted clones (TRAF3
 
 
 
/
 
 
 
) were transiently transfected
with a Cre expression vector (pBS185, a gift from C. Sigmund,
University of Iowa, Iowa City, IA) and subcloned to obtain ge-
neticin-sensitive clones. TRAF3
 
 
 
/
 
 
 
 cells that regained sensitivity
to geneticin were selected, and the targeting was repeated to dis-
rupt the remaining WT TRAF3 gene. Genomic PCR was per-
formed to screen the clones with both alleles targeted (TRAF3
 
 
 
/
 
 
 
)
using primer set 1 (neo-C and mT3-BT6) and set 3 (mT3-U5
and mT3-Y). TRAF3
 
 
 
/
 
 
 
 cells were transiently transfected with
the Cre expression vector again to remove the neo
 
r
 
 to allow the
use of geneticin selection in subsequent transfections.
 
In Vitro c-Jun Kinase Assay. 
 
A20.2J (4 
 
 
 
 10
 
6
 
) and CH12.LX
cells (2 
 
 
 
 10
 
6
 
) expressing human CD40 (hCD40)LMP1 were
stimulated with 10 
 
 
 
g/ml of anti–mouse CD40 (mCD40), anti-
hCD40, or isotype control Abs at 37
 
 
 
C for 10 or 20 min as indi-
cated in the figures. Cell lysates were prepared, and JNK activity
was measured as described previously (30). Reactions were sepa-
rated by SDS-PAGE, and phosphorylated GST-c-Jun was visual-
ized by autoradiography of dried gels.
 
NF-
 
 
 
B Luciferase Reporter Assay. 
 
A20.2J and CH12.LX cell
subclones (2 
 
 
 
 10
 
7
 
 cells) expressing hCD40LMP1 were elec-
troporated at 225 V and 50 mS with 38 
 
 
 
g 4X NF-
 
 
 
B 
 
firefly
 
 lu-
ciferase (a gift from E. Clark, University of Washington, Seattle,
WA) and 2 
 
 
 
g 
 
renilla
 
 (null) luciferase reporter plasmids (Pro-
mega). After transfection, cells were rested in medium containing
15% FCS overnight at 37
 
 
 
C. Cells were washed and resuspended
in BCM-10, aliquoted into 24-well plates (2 ml/well), and stim-
ulated with 10 
 
 
 
g of anti-mCD40, anti-hCD40, or isotype con-
trol mAbs for 5 h at 37
 
 
 
C. Cell lysates were analyzed for the 
 
firefly
 
and 
 
renilla
 
 luciferase activities with the Dual Luciferase Reporter
Assay kit (Promega) on a TD-20/20 Luminometer (Turner De-
signs) following the manufacturer’s protocol.
 
Surface Molecule Up-regulation. 
 
5 
 
 
 
 10
 
5 
 
A20.2J cells were
stimulated in six-well plates in a total volume of 5 ml with 2 
 
 
 
g/
ml of anti-mCD40, anti-hCD40, or isotype control mAbs for 48 h
at 37
 
 
 
C. For detection of CD23 and CD80, cells were stained with
FITC-labeled mAb against these surface antigens or FITC-labeled
isotype control mAb. For detection of CD95, cells were stained
with biotin-labeled anti-CD95 (Jo-2), followed by FITC-labeled
streptavidin. For detection of MHC class II, cells were stained with
anti-E
 
k
 
 (14–4-4S), followed by FITC-labeled goat anti–mouse
IgG2a Ab. Stained cells were subsequently analyzed by immuno-
fluorescence flow cytometry using a FACScan™ benchtop flow
cytometer (Becton Dickinson). Mean channel fluorescence was
determined using WinMDI 2.8 software (http://facs.scripps.edu).
 
Ab Secretion Assay. 
 
CH12.LX and its transfected subclones
express surface IgM specific for phosphatidylcholine, an Ag found
on the surface of sheep red blood cells (31). Enumeration of
SRBC-specific IgM-secreting cells was by direct plaque assay as
described previously (32). In brief, 1.5 
 
 
 
 10
 
3
 
 cells were stimu-
lated in 96-well plates in a total volume of 200 
 
 
 
l for 72 h. For
reconstituted TRAF3
 
 
 
/
 
 
 
 cells, TRAF3 expression was induced
by preincubation with BCM-10 containing 100 
 
 
 
M isopropyl-
 
 
 
- 
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d
 
-thiogalactopyranoside (IPTG) at 37
 
 
 
C for 24 h, and stimuli
were added for a subsequent 48 h. Ab-secreting cells were mea-
sured as cells capable of forming lytic plaques on a lawn of SRBCs
in the presence of complement and quantitated as plaque-forming
cells (Pfcs) per 10
 
6
 
 viable cells recovered from replicate cultures.
 
Cytokine ELISAs. 
 
For TNF
 
 
 
 secretion, 5 
 
 
 
 10
 
5
 
 CH12.LX
cells were stimulated with Sf9 cells infected with WT baculovi-
rus, or a recombinant baculovirus expressing mouse or human
CD154 at a ratio of B cells/Sf9 cells of 10:1, or 10 
 
 
 
g/ml of anti-
mCD40, anti-hCD40, or isotype control Ab in an anti-TNF–
coated ELISA plate for 3 h at 37
 
 
 
C. The amount of TNF
 
 
 
 in the
supernatant was measured by ELISA as described previously (33).
For IL-6 secretion, 10
 
5
 
 CH12.LX cells were stimulated with Sf9
cells infected with WT baculovirus, or a recombinant baculovirus
expressing mouse or human CD154 at an 8:1 ratio in a 96-well
plate for 48 h. The amount of IL-6 in the supernatant was deter-
mined by ELISA as described previously (34).
 
TRAF Recruitment to Receptors in Detergent-insoluble Micro-
domains (Rafts) and Immunoprecipitation. 
 
A20.2J and CH12.LX
subclones (2 
 
 
 
 10
 
7
 
 cells) expressing hCD40LMP1 were stimu-
lated in a total volume of 1 ml with 10 
 
 
 
g of anti-mCD40
(1C10), anti-hCD40 (G28–5), or isotype control mAbs for 10
min at 37
 
 
 
C to induce recruitment of TRAFs to membrane rafts
and allow formation of CD40 or LMP1 signaling complexes. To
induce raft recruitment of TRAFs by CD40 signaling in the pres-
ence of LMP1, CH12.LX subclones expressing an IPTG-induc-
ible LMP1 were preincubated in BCM-10 containing 100 
 
 
 
M
IPTG for 24 h and cells were stimulated with anti-mCD40 Ab as
aforementioned. Cells were chilled on ice, lysed in 400 
 
 
 
l of ice-
cold 1% Brij 58 lysis buffer (35), and incubated for 30 min on ice.
Detergent-soluble and insoluble fractions were separated by cen-
trifugation at 14,000 
 
g
 
 for 30 min. The 1% Brij 58–insoluble pel-
lets were resolubilized in 400 
 
 
 
l of octylglucopyranoside lysis
buffer (36) and sonicated, followed by a 30-min incubation on
ice. The octylglucopyranoside lysates (raft lysates) were clarified
by centrifugation at 14,000 
 
g
 
 for 10 min to remove the remaining
insoluble materials. Samples (40 
 
 
 
l) of 1% Brij 58–soluble lysates
as well as the raft lysates were reserved and the remainder of the
lysates (360 
 
 
 
l) were immunoprecipitated with protein G–Sepha-
rose beads (Amersham Biosciences) prearmed with anti-mCD40
(an equal mixture of 1C10 and 4F11), or anti-hCD40 (G28–5)
for 3 h at 4
 
 
 
C. The immunoprecipitation complexes were
washed four times with lysis buffer and left in a final volume of
50 
 
 
 
l. Aliquots of lysates and the immunoprecipitates were sepa-
rated by SDS-PAGE and analyzed by immunoblot.
 
Online Supplemental Material. 
 
We provide here a detailed de-
scription of the mTRAF3 gene targeting construct, methods of
stable transfection of mouse B cell lines and immunoblot analysis,
PCR primers, and antibodies used in this paper. In addition, we
include further results that support those described here, includ-
ing PCR screening, titration experiments, cytokine ELISA,
quantitation data, detailed results of the second cell line, and
FACS
 
®
 
 profiles of surface molecule up-regulation. Online sup-
plemental material is available at http://www.jem.org/cgi/
content/full/jem.20031255/DC1.
 
Results
 
Generation of TRAF3
 
 
 
/
 
 
 
 B Cell Lines. 
 
To generate
TRAF3
 
   
 
 B cells, we first cloned 
 
 
 
23 kb of the
mTRAF3 gene using a PCR-based chromosomal walking
technique (Fig. 1 A). We generated TRAF3
 
   
 
 A20.2J
mouse B lymphoblastic leukemia cells and CH12.LX
mouse B lymphoma cells by successive homologous re-
combination using a mTRAF3 gene targeting construct as
described in Materials and Methods (Fig. 1 B and Fig.
S1, available at http://www.jem.org/cgi/content/full/
Figure 1. Targeted disruption of the mouse TRAF3
gene. (A) Schematic diagrams of the mTRAF3 gene
and spliced mRNA are shown. Exons are depicted
(open boxes); lengths of introns are shown. UTR, un-
translated region. (B) Schematic diagrams of the targeting
vector, the initial targeted locus, and the final targeted
locus after transfection with the DNA recombinase Cre
are shown. The translation start codon of mTRAF3
(ATG), the neomycin resistance cassette (Neor), the
diphtheria toxin subunit A cassette (DT-A), loxP sites
(recognition sites for Cre, lox), and an SV40 polyade-
nylation signal sequence (pA) are indicated. PCR
primers used to screen B cell clones for homologous
recombination are indicated with arrows. (C) Total cell
lysates were prepared from WT ( / ), TRAF3 / 
( / ), and TRAF3 /  ( / ) A20.2J and CH12.LX
cells. Protein blots were immunoblotted for TRAF3,
stripped, and reimmunoblotted for TRAF2 and
TRAF6. (D) WT (TRAF3 / ) and TRAF3 /  A20.2J
stably transfected with hCD40LMP1 were analyzed by
immunofluorescence flow cytometry using FITC-labeled
anti-hCD40 (shaded) or isotype control Ab (unshaded).
All transfectants used in this analysis, including those of
CH12.LX cells, were expression matched in this manner.
Results in all figures were repeated in three indepen-
dent experiments or as specified.CD40 and LMP1 Differentially Use TRAF3 to Signal to B Cells 664
jem.20031255/DC1). Neither full-length nor truncated
TRAF3 were detected in TRAF3    B cells by immuno-
blot analysis (Fig. 1 C). The abundance of other TRAF
molecules, such as TRAF2 and TRAF6, was not affected
by TRAF3 deficiency (Fig. 1 C).
Effects of TRAF3 Deficiency on Early Signaling Events.
LMP1 self-aggregates through its six transmembrane do-
mains and, thus, is constitutively active when it is expressed
on cells (8, 12, 13). It has been shown previously that only
the CCT of LMP1 is required for postaggregation delivery
of signals and that LMP1 signals similarly in both human
and mouse B cells (11, 13, 20). To study LMP1 signal-
ing, we stably transfected A20.2J and CH12.LX cells
with an expression vector encoding a chimeric molecule
(hCD40LMP1) composed of the extracellular and trans-
membrane domains of hCD40 and the CCT of LMP1.
This chimeric molecule signals indistinguishably from
LMP1, but with controllable initiation, and like LMP1, its
aggregation localizes the hybrid receptor to plasma mem-
brane rafts (21, 36). The extracellular domains of hCD40
and mCD40 are not cross-reactive with species–specific an-
tibodies, so hCD40LMP1 and the endogenous mCD40 can
be engaged differentially (21, 36). WT and TRAF3 /  B
cells stably expressing matched levels of hCD40LMP1 were
selected by immunofluorescence flow cytometry (Fig. 1 D)
and used in the following study.
First, we examined activation of the MAPK family ki-
nases and the transcription factor NF- B, reproducible
proximal signaling events induced by both CD40 and
LMP1 in B cells (5, 12, 37). Interestingly, TRAF3    B
cells displayed moderately enhanced CD40-mediated JNK
activation as compared with TRAF3    B cells. This was
seen using either agonistic Abs (Fig. 2 A) or CD154 (Figs.
S2 A and S3, available at http://www.jem.org/cgi/content/
full/jem.20031255/DC1) as a stimulus. CD40-mediated ac-
tivation of p38, NF- B, Akt, and ERK was unaltered in both
TRAF3    B cell lines (Fig. S2 A and not depicted). Previ-
ous papers in which DN or WT TRAF3 were overex-
pressed suggest that TRAF3 does not affect LMP1-medi-
ated JNK activation and inhibits LMP1-mediated NF- B
Figure 2. Effects of TRAF3 deficiency
on activation of JNK, p38, and NF- B
by CD40 and LMP1 signaling. (A) A20.2J
cells were stimulated with anti-mCD40
Ab ( -mCD40) for the indicated times.
Lysates were immunoblotted for phos-
phorylated JNK (P-JNK), total JNK
(JNK), and TRAF3. (B) A20.2J cells stably
transfected with hCD40LMP1 were stim-
ulated with isotype control Abs (iso1 and
iso2) or anti-mCD40 Ab (CD40) for 5
min, or anti-hCD40 Ab to trigger signal-
ing through hCD40LMP1 (LMP1) for
the indicated times. Lysates were immu-
noblotted for phosphorylated (P-) or total
JNK, p38, or I B , followed by TRAF3
and LMP1. (C) Cells as in B were stimu-
lated with anti-mCD40 Ab (CD40) for
10 min, anti-hCD40 Ab (LMP1) for
20 min, or isotype control Abs (iso1 and
iso2). JNK activity was determined by an
in vitro c-Jun kinase assay and indicated
by the level of phosphorylated GST-
c-Jun. (D) Cells as in B were transiently
transfected with a NF- B firefly reporter
plasmid and a renilla control plasmid,
stimulated with antibodies as in B for 5 h.
Relative light units (RLUs) were calcu-
lated by normalizing the firefly activity to
the renilla activity in each sample. (E) Re-
constituted TRAF3 /  A20.2J cells were
preincubated in the absence (-IPTG) or
presence of IPTG ( IPTG) for 24 h,
stimulated with anti-mCD40 Ab ( -
mCD40) for the indicated times. (F) Re-
constituted TRAF3 /  A20.2J cells were
preincubated in the absence (-IPTG) or
presence of IPTG ( IPTG) for 24 h,
stimulated with isotype control Abs (iso1
and iso2) or anti-mCD40 Ab (CD40) for
10 min, or anti-hCD40 Ab to trigger sig-
naling through hCD40LMP1 (LMP1) for
the indicated times. Activation of JNK,
p38, and NF- B were analyzed as in B.Xie et al. 665
activation (17, 38). Surprisingly, we found that activation
of JNK by LMP1 signaling was markedly defective in
TRAF3    B cells as measured by immunoblot analysis as
well as by an in vitro c-Jun kinase assay (Fig. 2, B and C,
and Figs. S4 A and S5 A, available at http://www.jem.org/
cgi/content/full/jem.20031255/DC1). Furthermore, acti-
vation of p38 and degradation of I B  (the inhibitory sub-
unit of NF- B) induced by LMP1 signaling were severely
impaired in TRAF3    B cells (Fig. 2 B and Fig. S4 A). In
contrast, activation of Akt and ERK by LMP1 signaling
was normal in TRAF3    B cells (Fig. S5 B). We con-
firmed the inhibitory effect of TRAF3 deficiency on
LMP1-mediated NF- B activation (a consistent twofold
inhibition compared with WT cells) by a luciferase reporter
assay (Fig. 2 D).
To verify that the reduced ability of TRAF3 /  B cells
to activate JNK, p38, and NF- B in response to LMP1 sig-
naling was caused by the loss of TRAF3, we stably trans-
fected an IPTG-inducible TRAF3 expression construct
into TRAF3 /  B cells. Even in the absence of IPTG, a
low level of TRAF3 expression restored the activation of
JNK, p38, and NF- B in response to LMP1 signaling (Fig.
2 F and Fig. S4 B). Restoration of TRAF3 expression to
WT levels with IPTG induction further enhanced JNK ac-
tivation induced by LMP1 signaling (Fig. 2 F and Fig. S4
B), but modestly inhibited that induced by CD40 engage-
ment in both B cell lines (Fig. 2 E and Figs. S2 B and S3).
Titration of the stimuli used in these experiments con-
firmed the conclusion that TRAF3 is required for LMP1-
but not CD40-induced JNK activation (Fig. S6, available at
http://www.jem.org/cgi/content/full/jem.20031255/DC1).
Together, our data define a negative role for normal levels
of TRAF3 in CD40-mediated JNK activation, but in con-
trast, an unexpected requirement for TRAF3 in LMP1-
induced activation of JNK, p38, and NF- B. These find-
ings suggest that TRAF3 expressed at endogenous levels
plays roles in signaling that are not revealed by studies using
overexpression of TRAF3.
Effects of TRAF3 Deficiency on Effector Functions.  Next,
we determined if the effects of TRAF3 deficiency on early
signaling pathways of CD40 and LMP1 are predictive of
downstream B cell effector functions, including up-regula-
tion of surface molecules and secretion of cytokines and
antibodies. After CD40 engagement, TRAF3-deficient
A20.2J cells exhibited up-regulation of CD23 and CD95
similar to that of WT cells (summarized in Fig. 3 A; repre-
sentative histograms shown in Fig. S7, available at http://
www.jem.org/cgi/content/full/jem.20031255/DC1). Al-
though we consistently observed a partial decrease in
CD40-mediated up-regulation of CD80 in TRAF3    B
cells (Fig. 3 A), it may be due to clonal variation because
different A20.2J subclones vary in this response (not de-
picted). Using the mCD40-elicited response as an internal
control for each subclone, we found that LMP1-induced
up-regulation of CD23 and CD80 was reduced approxi-
mately two- and threefold, respectively, whereas up-regu-
lation of CD95 and MHC class II was not affected by
TRAF3 deficiency in A20.2J cells (Fig. 3 A and Fig. S7).
For detection of cytokine secretion, the membrane ligands
for hCD40 and mCD40 (hCD154, mCD154, respectively)
were also used, as they are more potent activators of this
specific function of CD40. Although mCD154 is capable
of activating hCD40 to a certain extent (39), cross-reaction
between hCD154 and mCD40 is negligible (21). Neither
CD40- nor LMP1-mediated secretion of TNF  and IL-6
was affected by TRAF3 deficiency in CH12.LX cells
(Fig. S8, available at http://www.jem.org/cgi/content/
full/jem.20031255/DC1). Interestingly, TRAF3    CH12.LX
Figure 3. Effects of TRAF3 deficiency
on effector functions of CD40 and LMP1.
(A) A20.2J cells stably transfected with
hCD40LMP1 were stimulated with 2  g/ml
anti-mCD40 Ab (CD40), anti-hCD40 Ab
to trigger signaling through hCD40LMP1
(LMP1), or isotype control Abs for each
(iso1 and iso2) for 48 h. Expression of
CD23, CD80, and CD95 was determined
by immunofluorescence staining and ana-
lyzed by flow cytometry. MCF, mean channel
fluorescence. Values presented are the
mean   SEM of three independent experi-
ments. (B) CH12.LX cells stably transfected
with hCD40LMP1 were stimulated with Abs
as in A for 72 h and assayed for IgM secre-
tion. Plaque-forming cells (Pfcs, IgM-secret-
ing cells) per 106 viable recovered cells are
shown. Values presented are the mean   SE
of replicate samples. Data are representative of
three independent experiments. (C) TRAF3 / 
CH12.LX cells stably transfected with hCD40LMP1 were stably supertransfected with an IPTG-inducible TRAF3 (Reconstituted TRAF3 / ). Recon-
stituted cells were preincubated in the absence ( IPTG) or presence of IPTG ( IPTG) for 24 h and stimulated with Abs as in B in the absence or presence
of IPTG, whereas TRAF3 /  cells were stimulated with Abs as in B in the absence of IPTG. IgM-secreting cells were enumerated as in B. Values presented
are the mean   SE of replicate samples. Data are representative of three independent experiments. (D) Expression of TRAF3 in the reconstituted
TRAF3 /  CH12.LX cells (Recon.) in the absence ( ) or presence of IPTG ( IPTG), compared with that of WT ( / ) and TRAF3 /  ( / )
cells, was analyzed by immunoblotting. An immunoblot for actin served as loading control.CD40 and LMP1 Differentially Use TRAF3 to Signal to B Cells 666
cells exhibited enhanced IgM secretion after CD40 engage-
ment, but profoundly suppressed IgM secretion in response
to LMP1 signaling as compared with TRAF3    cells (Fig.
3 B). We further verified this observation by examining
TRAF3    CH12.LX cells reconstituted with an IPTG-
inducible TRAF3. Induction of TRAF3 expression with
IPTG completely restored IgM secretion in response to
LMP1 signaling, while decreasing IgM secretion mediated
by CD40 signaling (Fig. 3, C and D). These results extend
our previous finding that overexpression of TRAF3 de-
creases CD40-mediated IgM secretion (29), and in con-
trast, highlight the importance and indispensability of
TRAF3 in LMP1-induced B cell activation. Furthermore,
we also stably transfected an IPTG-inducible full length
LMP1 into WT and TRAF3    B cells. A similar require-
ment for TRAF3 was observed when the signal was deliv-
ered by inducible full-length LMP1 (unpublished data).
TRAF2 Recruitment and Degradation in TRAF3 /  B
Cells.  We found previously that both TRAF2 and
TRAF3 are recruited to membrane rafts upon CD40 or
LMP1 signaling (21, 35). To begin to understand how
TRAF3 differentially regulates CD40 and LMP1 signaling,
we examined whether the amount of TRAF2 recruitment
by CD40 or LMP1 signaling is changed in the absence of
TRAF3. In TRAF3 /  B cells, quantification of Western
blot band density showed that  60% more TRAF2 (as
compared with WT cells) was recruited to detergent-insol-
uble raft fractions and coimmunoprecipitated with CD40
upon CD40 engagement (Fig. 4 A). Considering that
TRAF2 is important for CD40-induced JNK activation
and IgM secretion (24), our finding suggests that TRAF3
may exert its inhibitory effects on CD40 signaling by com-
peting with TRAF2 for association with CD40.
In light of numerous findings that TRAF2 is important
for LMP1-mediated NF- B and JNK activation (for re-
views see references 12, 13), we investigated the possibility
that defective LMP1 signaling in TRAF3 /  B cells was an
indirect result of alterations in the interaction between
TRAF2 and LMP1. However, we found no defects in the
association of TRAF2 with LMP1 in TRAF3 /  B cells as
measured by recruitment of TRAF2 to detergent-insoluble
membrane rafts or by coimmunoprecipitation of TRAF2
with LMP1 (Fig. 4 B). We have reported previously that
both TRAFs are degraded after CD40- but not LMP1-
induced signaling, suggesting that failure to degrade TRAFs
may contribute to the more pronounced and sustained ef-
fect of LMP1 on B cell activation (21, 40). Thus, we also
investigated the possibility that TRAF2 might undergo
degradation in response to LMP1 signaling in the absence
of TRAF3. However, this was not evident (Fig. 4 C), indi-
cating that the functional defects in LMP1 signaling were
directly related to the loss of TRAF3.
TRAF2-independence of LMP1 Signaling to B Cells.
Previous studies in which DN or WT TRAF2 were over-
expressed have led to the conclusion that TRAF2 is essen-
tial for LMP1-induced activation signals (12, 13). How-
ever, it is notable that in WT B cells, only  5% of cellular
TRAF2, but the majority ( 80%) of cellular TRAF3, was
recruited to detergent-insoluble membrane rafts upon
LMP1 signaling (Fig. 4 B). This is consistent with the ob-
servation that in EBV-transformed B lymphocytes, most of
TRAF3 and very little TRAF2 are associated with LMP1
(17, 41). This prompted us to test the requirement for
TRAF2 in LMP1 signaling using TRAF2 /  B cell lines
that we have generated (24). Surprisingly, LMP1-mediated
activation of JNK and NF- B in both TRAF2 /  B cell
lines was as robust as that observed in WT cells (Fig. 5, A
and B, and Fig. S9, available at http://www.jem.org/cgi/
content/full/jem.20031255/DC1), although CD40-medi-
ated JNK activation was compromised by TRAF2 defi-
ciency (Fig. 5 A and Fig. S9; reference 24). Furthermore,
LMP1-mediated IgM secretion was also intact in TRAF2 / 
Figure 4. Recruitment and degradation
of TRAFs in TRAF3    B cells. (A) A20.2J
cells were stimulated with anti-mCD40 Ab
to trigger signaling through endogenous
CD40 (CD40) or an isotype control Ab
(iso) for 10 min. Detergent soluble (S) and
insoluble raft (I) lysates were prepared. 90%
of the lysates were incubated with anti-
mCD40 Ab (an equal mixture of 1C10 and
4F11) to immunoprecipitate mCD40. The
lysates and immunoprecipitates were analyzed
by immunoblotting for TRAF2 and TRAF3.
(B) A20.2J cells stably transfected with
hCD40LMP1 were stimulated with anti-
hCD40 Ab to trigger signaling through
hCD40LMP1 (LMP1) or an isotype control
Ab (iso) for 10 min. Detergent soluble (S)
and insoluble raft (I) lysates were prepared.
90% of the lysates were incubated with anti-
hCD40 Ab (G28-5) to immunoprecipitate
hCD40LMP1. The lysates and immunopre-
cipitates were analyzed by immunoblotting for TRAF2, TRAF3, and LMP1. (C) Cells as in B were stimulated with isotype control Abs (iso1 and iso2)
or anti-mCD40 Ab (CD40) for 4 h, or anti-hCD40 Ab to trigger signaling through hCD40LMP1 (LMP1) for the indicated times. Lysates were immuno-
blotted for TRAF2, followed by TRAF3, LMP1, and actin. Similar results were obtained with CH12.LX cells.Xie et al. 667
CH12.LX cells (Fig. 5 C), although CD40-mediated IgM
secretion was decreased in these cells (Fig. 5 C; reference
24). Our data indicate that TRAF2 appears dispensable for
many LMP1-induced B cell activation events.
TRAF1 Is Not Required for LMP1-induced JNK Activation.
A recent work has implied a critical role for TRAF1 in
LMP1-induced JNK activation (38). We noticed a striking
difference in the expression level of TRAF1 between the
two B cell lines we studied. Expression of TRAF1 is barely
detectable but inducible by CD40 and LMP1 signaling in
A20.2J cells (Fig. 6 A), whereas CH12.LX cells constitu-
tively express higher levels of TRAF1 (Fig. 6 B). Never-
theless, both cell lines activate JNK similarly in response to
LMP1 signaling, which is inconsistent with a critical role
for TRAF1 in this function. However, it may be that only
small amounts of TRAF1 are sufficient for signaling. Thus,
we further tested the role of TRAF1 in LMP1-induced
JNK activation by examining TRAF1 /  CH12.LX cells
(unpublished data), generated using the same approach as
that used to produce TRAF2 /  and TRAF3 /  cells. In
TRAF1 /  CH12.LX cells, activation of JNK by either
CD40 or LMP1 signaling was intact (Fig. 6 B). Our obser-
vation is consistent with the previous finding that B cells
isolated from TRAF1 /  mice activate JNK normally in
response to engagement of CD40 (42), and indicates that,
at least in B cells, TRAF1 is not essential for LMP1-medi-
ated JNK activation.
Effects of TRAF3 Deficiency on Simultaneous CD40 and
LMP1 Signaling in B Cells.  Because simultaneous CD40
and LMP1 signaling may occur in EBV-infected B cells in
vivo in situations where CD154 is available, it would be
interesting to know how TRAF3 deficiency affects simul-
taneous LMP1 and CD40 signaling. We found that CD40
and LMP1 signaling synergistically induced JNK activation
in WT B cells at early time points (10 and 30 min) after en-
gagement. In contrast, such synergistic effects observed in
WT B cells were inhibited in TRAF3 /  cells by approxi-
mately threefold (Fig. 7 A and Fig. S10, available at http://
www.jem.org/cgi/content/full/jem.20031255/DC1). CD40
and LMP1 additively induced NF- B activation in both
WT and TRAF3    B cells. However, the level of NF- B
activation induced by simultaneous CD40 and LMP1 sig-
naling observed in TRAF3    B cells is  60% of that of
WT B cells due to the inhibitory effect of TRAF3 defi-
ciency on LMP1-mediated NF- B activation (Fig. 7 B).
We have reported previously that CD40 and LMP1 coop-
erated to induce antibody secretion in WT B cells (20). In-
terestingly, such enhancing effects of CD40 and LMP1 on
antibody secretion were completely abolished in TRAF3   
B cells (Fig. 7 C). Together, our data indicate that deletion
of TRAF3 can dramatically affect the outcome of simulta-
neous CD40 and LMP1 signaling.
TRAF Recruitment by CD40 Signaling in the Presence of
LMP1 in B Cells.  In light of the evidence that LMP1
signaling may sequester most cellular TRAF3 (Fig. 4 B;
references 17, 41), we predict that ongoing LMP1 signal-
ing may cause changes in CD40-mediated TRAF recruit-
ment and that such changes in TRAF recruitment may
Figure 5. TRAF2-independent LMP1 signaling in B cells.
(A) A20.2J cells stably transfected with hCD40LMP1 were
stimulated with isotype control Abs (iso1 and iso2) or anti-
mCD40 Ab (CD40) for 10 min, or anti-hCD40 Ab for the indi-
cated times to trigger signaling through hCD40LMP1 (LMP1).
Cell lysates were analyzed by immunoblotting for phosphorylated
(P-) or total JNK or I B , followed by TRAF2 and LMP1.
(B) Cells as in A were transiently transfected with a NF- B firefly
luciferase reporter plasmid and a renilla control plasmid, stimu-
lated with isotype control Abs (iso1 and iso2), anti-mCD40 Ab
(CD40), or anti-hCD40 Ab to trigger signaling through
hCD40LMP1 (LMP1) for 5 h. RLU, relative light unit. Values
presented are the mean   SE of triplicate samples. Data are rep-
resentative of three independent experiments. (C) CH12.LX
cells stably transfected with hCD40LMP1 were stimulated with
Abs as in B for 72 h, and assayed for IgM secretion. Plaque-
forming cells (Pfcs) per 106 viable recovered cells are shown.
Values presented are the mean   SE of replicate samples. Data
are representative of three independent experiments.
Figure 6. TRAF1 is inducible
but not required for JNK activa-
tion by LMP1 signaling in B
cells. (A) A20.2J cells stably trans-
fected  with hCD40LMP1 were
stimulated with isotype control
Abs (iso1 and iso2) or anti-
mCD40 Ab (CD40) for 4 h, or
anti-hCD40 Ab to trigger sig-
naling through hCD40LMP1
(LMP1) for the indicated times.
Lysates were immunoblotted for
TRAF1, followed by actin. A
nonspecific  band (NS) in the
TRAF1 blot is indicated. (B)
WT and TRAF1 /  CH12.LX
cells stably transfected with
hCD40LMP1 were stimulated
with Sf9 cells infected with WT
baculovirus (Sf9) or a recombi-
nant baculovirus-expressing mouse
CD154 (mCD154), an isotype control Ab (iso), or anti-hCD40 Ab to
trigger signaling through hCD40LMP1 (LMP1) for 30 min. Cell lysates
were analyzed by immunoblotting for phosphorylated (P-) or total JNK,
followed by TRAF1 and LMP1.CD40 and LMP1 Differentially Use TRAF3 to Signal to B Cells 668
contribute to the synergistic effects of simultaneous CD40
and LMP1 signaling observed in TRAF3 /  B cells. To
address this possibility, we measured TRAF recruitment by
CD40 signaling in the presence of LMP1 signaling by us-
ing B cell lines stably transfected with an IPTG-inducible
full-length LMP1. As shown in Fig. 8, in LMP1-expressing
B cells,  50% more TRAF2 (as compared with untrans-
fected cells, measuring band intensity by a low-light imag-
ing system) was recruited to detergent-insoluble raft frac-
tion and coimmunoprecipitated with CD40, whereas
 70% less TRAF3 was coimmunoprecipitated with CD40
upon CD40 engagement (Fig. 8). Considering that
TRAF2 plays positive roles, whereas TRAF3 plays nega-
tive roles in CD40-induced JNK activation and IgM secre-
tion (Figs. 2 and 3 and Figs. S2 and S3; reference 24), the
changes in TRAF2 and TRAF3 recruitment upon CD40
engagement in the presence of LMP1 signaling suggest am-
plified CD40 signals and, thus, may partially account for
the synergistic effects of simultaneous CD40 and LMP1
signaling observed in WT B cells.
Discussion
The functional contribution of TRAF3, an adaptor pro-
tein used by both CD40 and its viral oncogenic mimic
LMP1, has long remained unclear (13, 37). To better un-
derstand the biologic roles played by TRAF3 while cir-
cumventing the early lethality of TRAF3 /  mice (23), we
have generated two TRAF3 /  mouse B cell lines by ap-
plying a novel somatic cell gene targeting strategy. Detailed
comparison of CD40 and LMP1 signaling between WT
and TRAF3 /  B cells has allowed us to delineate the spe-
cific roles of TRAF3.
The role of TRAF3 in CD40-mediated signaling has
been controversial. When fetal liver cells from TRAF3 / 
embryos were used to reconstitute lethally irradiated mice,
TRAF3 /  B cells purified from spleens of these chimeric
mice respond to CD154 normally in proliferation or up-
regulation of CD23 and CD80 (23). Therefore, TRAF3 ap-
pears dispensable for these CD40 function in B cells, but
more detailed analysis was not performed. The Ramos B
cell line stably transfected with DN TRAF3 shows de-
creased CD40-mediated activation of JNK and p38, cyto-
kine secretion, and Ig production compared with untrans-
fected parent cells (43). We have shown previously that
inducible overexpression of either full-length or DN
TRAF3 inhibits CD40-mediated IgM secretion, suggesting
that TRAF3 exerts this effect by competition with TRAF2
(29). In the present paper, we demonstrated that CD40-
mediated JNK activation and IgM production were enhanced,
whereas CD40-induced activation of p38 and secretion of
TNF  and IL-6 were unaltered by TRAF3 deficiency in B
cells. Our results support a negative or neutral role for
TRAF3 in CD40 signaling. The inhibitory effect of DN
Figure 7. Effects of TRAF3 deficiency on simultaneous
CD40 and LMP1 signaling in B cells. (A) A20.2J cells stably
transfected with hCD40LMP1 were stimulated with 1  g/ml
of isotype control Abs (iso), anti-mCD40 Ab (CD40),
anti-hCD40 Ab to trigger signaling through hCD40LMP1
(LMP1), alone or in combination for the indicated times.
Cell lysates were analyzed by immunoblotting for phos-
phorylated (P-) or total JNK, followed by TRAF3 and
LMP1. (B) Cells as in A were transiently transfected with a
NF- B firefly luciferase reporter plasmid and a renilla control
plasmid and stimulated with Abs as in A for 5 h. RLU,
relative light unit. Values presented are the mean   SE of
replicate samples. Data are representative of three independent
experiments. (C) CH12.LX cells stably transfected with
hCD40LMP1 were stimulated with Abs (250 ng/ml of
each Ab) as in A for 72 h and assayed for IgM secretion.
Plaque-forming cells (Pfcs) per 106 viable recovered cells
are shown. Values presented are the mean   SE of repli-
cate samples. Data are representative of two independent
experiments.
Figure 8. Recruitment of TRAFs by CD40 signaling in the presence of
LMP1. CH12.LX cells stably transfected with an IPTG-inducible wild-
type full length LMP1 (WT LMP1) or untransfected control cells
(CH12.LX) were preincubated with BCM-10 containing 100  M IPTG
for 24 h and stimulated with anti-mCD40 Ab to trigger signaling through
endogenous CD40 (CD40) or an isotype control Ab (iso) for 10 min. Deter-
gent soluble (S) and insoluble raft (I) lysates were prepared. 90% of the lysates
were incubated with anti-mCD40 Ab (an equal mixture of 1C10 and
4F11) to immunoprecipitate mCD40. The lysates and immunoprecipitates
were analyzed by immunoblotting for TRAF2, TRAF3, and LMP1.Xie et al. 669
TRAF3 on CD40-mediated signaling in Ramos B cells (43)
may result from an inhibition of the association of other
TRAF molecules (such as TRAF1, -2, and -5) with CD40.
Little was known previously about the role of TRAF3
in LMP1 signaling, although it was known that among all
TRAFs, TRAF3 binds to LMP1 most avidly (8, 13, 17,
44). Previous analyses in which WT or DN TRAF3 were
overexpressed suggest a negative role for TRAF3 in
LMP1-medated activation of NF- B and induction of
gene expression (17, 45). However, here we provided sev-
eral lines of evidence demonstrating that TRAF3 plays
positive roles and is indispensable for LMP1 signaling. Our
results indicate that TRAF3 is critical for LMP1-induced
activation of JNK, p38, and NF- B, up-regulation of sur-
face molecules CD23 and CD80, as well as antibody secre-
tion. Notably, we also observed that activation of ERK
and Akt, up-regulation of CD95, as well as secretion of
TNF  and IL-6 in response to LMP1 signaling were intact
in TRAF3 /  B cells, suggesting that this subset of LMP1
signaling events is TRAF3-independent or that redun-
dancy exists. Further study is needed to identify the factors
that are responsible for the residual LMP1 signaling ob-
served in TRAF3 /  B cells. Candidate molecules include
other adaptor proteins shown previously to be able to in-
teract with LMP1, such as TRAF5, receptor-interacting
protein, and TNF-R–associated DD protein (18, 46), and
perhaps TRAF1 and -2 may share overlapping functions
with these factors.
The general belief that TRAF2 but not TRAF3 is im-
portant for LMP1-mediated signaling arose from studies in
which overexpression of WT or DN TRAF molecules was
used, mostly with the human embryonic kidney cell line
293 (for reviews see references 12, 13). Because TRAF2 is
well known as a powerful activator of positive signals by
the receptors to which it binds (47, 48), the conclusion that
TRAF2 is the major mediator of LMP1-induced activation
seemed reasonable and expected. These overexpression ap-
proaches provided valuable initial direction, but verifica-
tion with endogenous molecules in the specific cell type of
interest is also necessary (8, 13). In the present work, evalu-
ation of LMP1 signaling in two TRAF2 /  B cell lines has
revealed that LMP1-mediated activation of JNK and NF-
 B as well as antibody secretion were intact in the absence
of TRAF2. In contrast, CD40-mediated JNK activation
and IgM secretion were dramatically inhibited by TRAF2
deficiency (24). Our findings indicate that TRAF2 plays
important roles in CD40 signaling, but is dispensable for
many LMP1-mediated signaling events in B cells. There-
fore, by characterizing B cell lines individually deficient in
TRAF2 and TRAF3, we have demonstrated that CD40
and LMP1 differentially use TRAF2 and TRAF3, and that
TRAF3 is required and critical for LMP1 signaling.
How TRAF3 differentially regulates and participates in
CD40 and LMP1 signaling awaits further investigation, al-
though our data suggest that TRAF3 may exert its inhibi-
tory effects on CD40 signaling by competing with TRAF2
for association with CD40. Although CD40 appears to
have much greater avidity for TRAF2 compared with
LMP1, LMP1 binds TRAF3 with high avidity (8, 13, 17,
44). These differences may play an important role in
TRAF3’s differential regulation of the two receptors. One
previous paper has shown that forced localization of
TRAF3 to the cell membrane by NH2-terminal myristoy-
lation is sufficient to convert it into an activator of JNK in
293 cells (49). However, both CD40 and LMP1 recruit
TRAF3 to membrane rafts (21, 35), yet expression of nor-
mal levels of TRAF3 promoted LMP1-induced JNK acti-
vation in B cells, whereas it inhibited JNK activation in-
duced by CD40. Therefore, it appears that translocation to
membrane rafts is necessary to enable TRAF3 to regulate
JNK activation, but is not sufficient to determine the out-
come of TRAF3 binding. Distinct structural features of
CD40 and LMP1 cytoplasmic tails and/or additional factors
present in the signaling rafts of these two receptors may be
essential in determining the nature of TRAF3 function.
Identification of such structural determinants of CD40 and
LMP1, and delineation of the profiles of factors assembled
in the signaling rafts will be key to further elucidate the
precise role of TRAF3 in CD40 and LMP1 signaling.
In addition to CD40 and LMP1, members of the large
and diverse TNF-R superfamily have been shown to inter-
act with one or more of the TRAF family members, and
members of the Toll/interleukin-1 receptor family also
bind to TRAF6 (47, 48, 50), emphasizing the broad im-
portance of this family of adaptor proteins in immune regu-
lation. For example, TRAF3 is also used by CD27, CD30,
LT -R, RANK, ATAR, OX40, 4–1BB, and BAFF-R
(47, 48, 50, 51). Cell lines deficient in specific TRAFs
should be valuable in dissecting the specific roles of each
TRAF molecule in the signaling pathways of these recep-
tors. Additionally, this approach will allow in the future the
production of cell lines deficient in multiple TRAFs, thus
enabling the delineation of pathways in which TRAFs play
overlapping or partially redundant roles.
In summary, the present work illustrates the power of
our new approach in revealing an unexpected, critical role
for TRAF3 in mediating signaling to B cells by the viral
oncogenic mimic of CD40, LMP1. Our findings could
have important biological implications for how LMP1
transforms B cells. This viral oncoprotein can use, and po-
tentially sequester a TRAF that normally inhibits signaling.
Furthermore, LMP1 can be independent of the levels of
TRAF2 available, so the tighter binding of TRAF2 by
other receptors will not limit LMP1 signals. Because LMP1
does not induce degradation of TRAF3 after its binding, as
does CD40 (21), the TRAF3-mediated signals can be fur-
ther sustained. These sharp contrasts in the way a receptor
and its viral mimic use the same TRAFs may make critical
contributions to EBV-mediated pathogenesis, and raise the
intriguing possibility that TRAF3 may serve as a potential
therapeutic target in EBV-associated malignancies.
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